Skyclarys Fight for Rare Disease Access | Ireland News

Friedreich’s Ataxia patients in Ireland are on the brink of historic change as Skyclarys, the first treatment to slow this rare disease’s progression, faces a crucial HSE decision. Initially rejected for being too costly—€280,000 per patient annually—the drug now has new support from a Rare Diseases review group. Families have campaigned fiercely, even prompting a High Court case for urgent access. With Ireland holding the EU Presidency and global rare disease momentum building, pressure is mounting. The HSE Drugs Group meets today, with a final decision expected by August 25th—potentially rewriting lives for hundreds. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7c50d379ba890f98